In Vivo Positron Emission Tomographic Imaging of Glial Responses to Amyloid-β and Tau Pathologies in Mouse Models of Alzheimer's Disease and Related Disorders

@article{Maeda2011InVP,
  title={In Vivo Positron Emission Tomographic Imaging of Glial Responses to Amyloid-$\beta$ and Tau Pathologies in Mouse Models of Alzheimer's Disease and Related Disorders},
  author={Jun Maeda and Ming-Rong Zhang and Takashi Okauchi and Bin Ji and Maiko Ono and Satoko Hattori and Katsushi Kumata and Nobuhisa Iwata and Takaomi C. Saido and John Q. Trojanowski and Virginia M. -Y. Lee and Matthias Staufenbiel and Takami Tomiyama and Hiroshi Mori and Toshimitsu Fukumura and Tetsuya Suhara and Makoto Higuchi},
  journal={The Journal of Neuroscience},
  year={2011},
  volume={31},
  pages={4720 - 4730}
}
Core pathologies of Alzheimer's disease (AD) are aggregated amyloid-β peptides (Aβ) and tau, and the latter is also characteristic of diverse neurodegenerative tauopathies. These amyloid lesions provoke microglial activation, and recent neuroimaging technologies have enabled visualization of this response in living brains using radioligands for the peripheral benzodiazepine receptor also known as the 18 kDa translocator protein (TSPO). Here, we elucidated contributions of Aβ and tau deposits to… 

Figures from this paper

High-contrast in-vivo imaging of tau pathologies in Alzheimer’s and non-Alzheimer’s disease tauopathies
TLDR
The in-vivo reactivity of 18F-PM-PBB3 with FTLD tau inclusion was strongly supported by neuropathological examinations of autopsied and biopsied brains derived from Pick′s disease, PSP and corticobasal degeneration patients who underwent PET scans.
Positron Emission Tomography in Animal Models of Tauopathies
TLDR
The utilities of PET and recently developed tracers for evaluating the pathophysiology in tauopathy animal models are discussed and the outstanding challenges are pointed out and future outlook in visualizing tau-related pathophysiological changes in brain of t Tauopathy disease animal models is proposed.
Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study
TLDR
In vivo evidence that astrocytosis occurs early in AD, preceding Aβ plaque deposition is provided, and age-dependent increases in Aβ deposition in APPswe cortex and hippocampus are demonstrated.
In Vivo Visualization of Tau Accumulation, Microglial Activation, and Brain Atrophy in a Mouse Model of Tauopathy rTg4510.
TLDR
The time-course of the [11C]PBB3- and TSPO-PET finding suggests that tau deposition triggers progressive neuroinflammation, and the sequential changes can be evaluated in vivo in mouse brains.
In vivo imaging of microglial activation by positron emission tomography with [11C]PBR28 in the 5XFAD model of Alzheimer's disease
TLDR
Evaluating the new TSPO tracer [11C]PBR28 as a marker for microglial activation in the 5XFAD transgenic mouse model of AD provided support of the suitability of this tracer for in vivo monitoring of microglia activation and assessment of treatment response in future studies using animal models of AD.
Comparative In Vitro and In Vivo Quantifications of Pathologic Tau Deposits and Their Association with Neurodegeneration in Tauopathy Mouse Models
TLDR
The present findings support the distinct utilities of 11C-PBB3 PET and MRI in rTg4510 and PS19 mice for quantitatively pursuing mechanisms connecting PET-detectable and PET-undetectable tau aggregations to neuronal death, which recapitulate 2 different modes of tau-provoked neurotoxicity.
Neuroprotective effect of mitochondrial translocator protein ligand in a mouse model of tauopathy
TLDR
Findings support a protective role for TSPO ligands in tauopathy, reducing neuroinflammation, neurodegeneration, and brain atrophy.
In Vivo Detection of Age- and Disease-Related Increases in Neuroinflammation by 18F-GE180 TSPO MicroPET Imaging in Wild-Type and Alzheimer's Transgenic Mice
TLDR
In vivo microPET imaging with a novel TSPO radioligand, 18F-GE180, detected significantly enhanced neuroinflammation during normal aging in WT mice and in response to AD-associated pathology in APP/PS1dE9 Tg mice, an AD mouse model, and may be useful for longitudinal monitoring of neuro inflammation during AD progression and treatment.
...
...

References

SHOWING 1-10 OF 57 REFERENCES
Visualization of brain amyloid and microglial activation in mouse models of Alzheimer's disease.
TLDR
Near-simultaneous monitoring of amyloid removal and microgliosis in APP23 mice following injection of anti-Abeta antibody demonstrated positive correlation between levels of initially existing amyloidal and antibody-induced microglial activation, suggesting the possibility of microglia overactivation in immunotherapy for subjects with abundant amyloids.
Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer's Disease Enabled by Positron Emission Tomography
TLDR
The results support the usefulness of the small animal-dedicated PET system in conjunction with high-specific radioactivity probes and appropriate Tg models not only for clarifying the mechanistic properties of amyloidogenesis in mouse models but also for preclinical tests of emerging diagnostic and therapeutic approaches to AD.
Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease.
TLDR
These findings suggest that either microglial activation is limited to later stages of severe AD or [11C](R)-PK11195 is too insensitive to detect the level of microglia activation associated with mild to moderate AD.
Imaging of Peripheral Benzodiazepine Receptor Expression as Biomarkers of Detrimental versus Beneficial Glial Responses in Mouse Models of Alzheimer's and Other CNS Pathologies
TLDR
Together, PBR expressions in astrocytes and microglia reflect beneficial and deleterious glial reactions, respectively, in diverse neurodegenerative disorders including AD, pointing to new applications of PBR imaging for monitoring the impact of gliosis on the pathogenesis and treatment of AD.
Quinoline and Benzimidazole Derivatives: Candidate Probes for In Vivo Imaging of Tau Pathology in Alzheimer's Disease
TLDR
Three novel compounds are introduced, 4-[2-(2-benzoimidazolyl)ethenyl]-N,N-diethylbenzenamine, 2-[(4-methylamino)phenyl]quinoline, and 2-(4-aminophenyl)quinoline), as candidate probes for in vivo imaging of tau pathology in the AD brain.
19F and 1H MRI detection of amyloid β plaques in vivo
TLDR
It is demonstrated here that an intravenously administered 19F-containing amyloidophilic compound labels brain plaques and allows them to be visualized in living mice by magnetic resonance imaging (MRI) using 19F and 1H, providing a new direction for specific noninvasive amyloids imaging without the danger of exposure to radiation.
Potential antecedent marker of Alzheimer disease
TLDR
Elevated [C]PIB binding in nondemented subjects suggests that [C].PIB amyloid imaging may be sensitive for detection of a preclinical Alzheimer disease state, and longitudinal studies will be required to determine the association of elevated [C.]P IB binding and risk of developing dementia of the Alzheimer type.
A Mouse Model of Amyloid β Oligomers: Their Contribution to Synaptic Alteration, Abnormal Tau Phosphorylation, Glial Activation, and Neuronal Loss In Vivo
TLDR
It is suggested that APP transgenic mice are a useful model of A β oligomer-induced pathology in the absence of amyloid plaques and that Aβ oligomers cause not only synaptic alteration but also other features of AD pathology.
In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: a PET and MRI study.
...
...